Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn SC, Young LS, Jirström K, Crown J, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ni Chonghaile T.

Clin Cancer Res. 2019 Aug 13. pii: clincanres.0713.2019. doi: 10.1158/1078-0432.CCR-19-0713. [Epub ahead of print]

PMID:
31409615
2.

Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.

Svensson MC, Borg D, Zhang C, Hedner C, Nodin B, Uhlén M, Mardinoglu A, Leandersson K, Jirström K.

Front Oncol. 2019 Mar 13;9:136. doi: 10.3389/fonc.2019.00136. eCollection 2019.

3.

Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer.

Micke P, Botling J, Mattsson JSM, Planck M, Tran L, Vidarsdottir H, Nodin B, Jirström K, Brunnström H.

Sci Rep. 2019 Feb 4;9(1):1319. doi: 10.1038/s41598-018-37722-0.

4.

Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma.

Lundgren S, Fagerström-Vahman H, Zhang C, Ben-Dror L, Mardinoglu A, Uhlen M, Nodin B, Jirström K.

Biomark Res. 2019 Jan 14;7:1. doi: 10.1186/s40364-018-0153-8. eCollection 2019.

5.

Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC.

Edlund K, Madjar K, Mattsson JSM, Djureinovic D, Lindskog C, Brunnström H, Koyi H, Brandén E, Jirström K, Pontén F, Rahnenführer J, Micke P, Hengstler JG.

J Thorac Oncol. 2019 Apr;14(4):628-640. doi: 10.1016/j.jtho.2018.12.022. Epub 2019 Jan 9.

6.

Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition.

Costas L, Lujan-Barroso L, Benavente Y, Allen NE, Amiano P, Ardanaz E, Besson C, Boeing H, Bueno-de-Mesquita B, Cervenka I, Fortner RT, Fournier A, Gunter M, Harlid S, Huerta JM, Jerkeman M, Jirström K, Kaaks R, Karakatsani A, Khaw KT, Kotanidou A, Lund E, Masala G, Mattiello A, Melin B, Menéndez V, Murphy N, Nieters A, Overvad K, Riboli E, Sacerdote C, Sánchez MJ, Schmidt JA, Sieri S, Tjønneland A, Trichopoulou A, Tumino R, Vermeulen R, Weiderpass E, de Sanjosé S, Agudo A, Casabonne D.

Am J Epidemiol. 2019 Feb 1;188(2):274-281. doi: 10.1093/aje/kwy259.

PMID:
30481275
7.

Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases.

Vidarsdottir H, Tran L, Nodin B, Jirström K, Planck M, Jönsson P, Mattsson JSM, Botling J, Micke P, Brunnström H.

Hum Pathol. 2019 Feb;84:221-230. doi: 10.1016/j.humpath.2018.10.009. Epub 2018 Oct 31.

PMID:
30389437
8.

Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients.

Tryggvadottir H, Huzell L, Gustbée E, Simonsson M, Markkula A, Jirström K, Rose C, Ingvar C, Borgquist S, Jernström H.

Front Oncol. 2018 Oct 12;8:428. doi: 10.3389/fonc.2018.00428. eCollection 2018.

9.

Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.

Borg D, Larsson AH, Hedner C, Nodin B, Johnsson A, Jirström K.

J Transl Med. 2018 Oct 24;16(1):290. doi: 10.1186/s12967-018-1668-3.

10.

Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis.

Berntsson J, Eberhard J, Nodin B, Leandersson K, Larsson AH, Jirström K.

Oncoimmunology. 2018 Jun 11;7(8):e1465165. doi: 10.1080/2162402X.2018.1465165. eCollection 2018.

11.

Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases.

Vidarsdottir H, Tran L, Nodin B, Jirström K, Planck M, Mattsson JSM, Botling J, Micke P, Jönsson P, Brunnström H.

Am J Clin Pathol. 2018 Oct 24;150(6):533-544. doi: 10.1093/ajcp/aqy083.

PMID:
30169783
12.

Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: A Multinational Cohort Study.

Murphy N, Ward HA, Jenab M, Rothwell JA, Boutron-Ruault MC, Carbonnel F, Kvaskoff M, Kaaks R, Kühn T, Boeing H, Aleksandrova K, Weiderpass E, Skeie G, Borch KB, Tjønneland A, Kyrø C, Overvad K, Dahm CC, Jakszyn P, Sánchez MJ, Gil L, Huerta JM, Barricarte A, Quirós JR, Khaw KT, Wareham N, Bradbury KE, Trichopoulou A, La Vecchia C, Karakatsani A, Palli D, Grioni S, Tumino R, Fasanelli F, Panico S, Bueno-de-Mesquita B, Peeters PH, Gylling B, Myte R, Jirström K, Berntsson J, Xue X, Riboli E, Cross AJ, Gunter MJ.

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1323-1331.e6. doi: 10.1016/j.cgh.2018.07.030. Epub 2018 Jul 26.

13.

A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk.

Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, Leesman G, Linke SP, Jirström K, Zhou W, Amini RM, Wärnberg F.

Clin Cancer Res. 2018 Dec 1;24(23):5895-5901. doi: 10.1158/1078-0432.CCR-18-0842. Epub 2018 Jul 27.

PMID:
30054280
14.

Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment.

Björner S, Rosendahl AH, Tryggvadottir H, Simonsson M, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Front Endocrinol (Lausanne). 2018 Jun 6;9:306. doi: 10.3389/fendo.2018.00306. eCollection 2018.

15.

Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma.

Heby M, Lundgren S, Nodin B, Elebro J, Eberhard J, Jirström K.

J Transl Med. 2018 Mar 14;16(1):66. doi: 10.1186/s12967-018-1444-4.

16.

Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.

Kaaks R, Fortner RT, Hüsing A, Barrdahl M, Hopper M, Johnson T, Tjønneland A, Hansen L, Overvad K, Fournier A, Boutron-Ruault MC, Kvaskoff M, Dossus L, Johansson M, Boeing H, Trichopoulou A, Benetou V, La Vecchia C, Sieri S, Mattiello A, Palli D, Tumino R, Matullo G, Onland-Moret NC, Gram IT, Weiderpass E, Sánchez MJ, Navarro Sanchez C, Duell EJ, Ardanaz E, Larranaga N, Lundin E, Idahl A, Jirström K, Nodin B, Travis RC, Riboli E, Merritt M, Aune D, Terry K, Cramer DW, Anderson KS.

Int J Cancer. 2018 Aug 1;143(3):515-526. doi: 10.1002/ijc.31335. Epub 2018 Mar 8.

17.

Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification.

Karnevi E, Dror LB, Mardinoglu A, Elebro J, Heby M, Olofsson SE, Nodin B, Eberhard J, Gallagher W, Uhlén M, Jirström K.

Oncotarget. 2017 Dec 15;9(5):6188-6200. doi: 10.18632/oncotarget.23486. eCollection 2018 Jan 19.

18.

Hormonal factors and pancreatic cancer risk in women: The Malmö Diet and Cancer Study.

Andersson G, Borgquist S, Jirström K.

Int J Cancer. 2018 Jul 1;143(1):52-62. doi: 10.1002/ijc.31302. Epub 2018 Feb 21.

19.

MMP7 Modulation by Short- and Long-term Radiotherapy in Patients with Rectal Cancer.

Stene C, Polistena A, Gaber A, Nodin B, Ottochian B, Adawi D, Avenia N, Jirström K, Johnson LB.

In Vivo. 2018 Jan-Feb;32(1):133-138.

20.

Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer.

Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Front Endocrinol (Lausanne). 2017 Nov 28;8:332. doi: 10.3389/fendo.2017.00332. eCollection 2017.

21.

Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.

Johansson ALV, Andersson TM, Hsieh CC, Jirström K, Cnattingius S, Fredriksson I, Dickman PW, Lambe M.

Int J Cancer. 2018 Apr 1;142(7):1343-1354. doi: 10.1002/ijc.31174. Epub 2017 Dec 4.

22.

Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.

Fortner RT, Schock H, Le Cornet C, Hüsing A, Vitonis AF, Johnson TS, Fichorova RN, Fashemi T, Yamamoto HS, Tjønneland A, Hansen L, Overvad K, Boutron-Ruault MC, Kvaskoff M, Severi G, Boeing H, Trichopoulou A, Papatesta EM, La Vecchia C, Palli D, Sieri S, Tumino R, Sacerdote C, Mattiello A, Onland-Moret NC, Peeters PH, Bueno-de-Mesquita HBA, Weiderpass E, Quirós JR, Duell EJ, Sánchez MJ, Navarro C, Ardanaz E, Larrañaga N, Nodin B, Jirström K, Idahl A, Lundin E, Khaw KT, Travis RC, Gunter M, Johansson M, Dossus L, Merritt MA, Riboli E, Terry KL, Cramer DW, Kaaks R.

Int J Cancer. 2018 Apr 1;142(7):1355-1360. doi: 10.1002/ijc.31164. Epub 2017 Dec 11.

23.

Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.

Hedner C, Borg D, Nodin B, Karnevi E, Jirström K, Eberhard J.

J Clin Pathol. 2018 May;71(5):451-462. doi: 10.1136/jclinpath-2017-204774. Epub 2017 Nov 14.

PMID:
29138285
24.

The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma.

Svensson MC, Warfvinge CF, Fristedt R, Hedner C, Borg D, Eberhard J, Micke P, Nodin B, Leandersson K, Jirström K.

Oncotarget. 2017 Jul 21;8(42):72108-72126. doi: 10.18632/oncotarget.19437. eCollection 2017 Sep 22.

25.

Infiltration of γ⁢δ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer.

Allaoui R, Hagerling C, Desmond E, Warfvinge CF, Jirström K, Leandersson K.

Cancer Biomark. 2017 Dec 8;20(4):395-409. doi: 10.3233/CBM-170026.

26.

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

Siesing C, Sorbye H, Dragomir A, Pfeiffer P, Qvortrup C, Pontén F, Jirström K, Glimelius B, Eberhard J.

PLoS One. 2017 Aug 11;12(8):e0182512. doi: 10.1371/journal.pone.0182512. eCollection 2017.

27.

Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.

Corvigno S, Frödin M, Wisman GBA, Nijman HW, Van der Zee AG, Jirström K, Nodin B, Hrynchyk I, Edler D, Ragnhammar P, Johansson M, Dahlstrand H, Mezheyeuski A, Östman A.

J Pathol Clin Res. 2017 Jul 24;3(3):214-224. doi: 10.1002/cjp2.74. eCollection 2017 Jul.

28.

Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer.

Topi G, Ehrnström R, Jirström K, Palmquist I, Lydrup ML, Sjölander A.

Eur J Cancer. 2017 Sep;83:279-289. doi: 10.1016/j.ejca.2017.06.013. Epub 2017 Jul 29.

PMID:
28763692
29.

The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study.

Berntsson J, Svensson MC, Leandersson K, Nodin B, Micke P, Larsson AH, Eberhard J, Jirström K.

Int J Cancer. 2017 Oct 15;141(8):1654-1666. doi: 10.1002/ijc.30869. Epub 2017 Jul 20.

30.

The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype.

Lundgren S, Karnevi E, Elebro J, Nodin B, Karlsson MCI, Eberhard J, Leandersson K, Jirström K.

J Transl Med. 2017 Jul 3;15(1):152. doi: 10.1186/s12967-017-1256-y.

31.

Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.

Wouters J, Vizoso M, Martinez-Cardus A, Carmona FJ, Govaere O, Laguna T, Joseph J, Dynoodt P, Aura C, Foth M, Cloots R, van den Hurk K, Balint B, Murphy IG, McDermott EW, Sheahan K, Jirström K, Nodin B, Mallya-Udupi G, van den Oord JJ, Gallagher WM, Esteller M.

BMC Med. 2017 Jun 5;15(1):101. doi: 10.1186/s12916-017-0851-3.

32.

Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies.

Nimptsch K, Song M, Aleksandrova K, Katsoulis M, Freisling H, Jenab M, Gunter MJ, Tsilidis KK, Weiderpass E, Bueno-De-Mesquita HB, Chong DQ, Jensen MK, Wu C, Overvad K, Kühn T, Barrdahl M, Melander O, Jirström K, Peeters PH, Sieri S, Panico S, Cross AJ, Riboli E, Van Guelpen B, Myte R, Huerta JM, Rodriguez-Barranco M, Quirós JR, Dorronsoro M, Tjønneland A, Olsen A, Travis R, Boutron-Ruault MC, Carbonnel F, Severi G, Bonet C, Palli D, Janke J, Lee YA, Boeing H, Giovannucci EL, Ogino S, Fuchs CS, Rimm E, Wu K, Chan AT, Pischon T.

Eur J Epidemiol. 2017 May;32(5):419-430. doi: 10.1007/s10654-017-0262-y. Epub 2017 May 26.

33.

High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.

Ahlin C, Lundgren C, Embretsén-Varro E, Jirström K, Blomqvist C, Fjällskog M-.

Breast Cancer Res Treat. 2017 Aug;164(3):667-678. doi: 10.1007/s10549-017-4294-5. Epub 2017 May 20.

34.

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O'Connor DP, Gallagher WM.

Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28.

35.

Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.

Lindquist KE, Karlsson A, Levéen P, Brunnström H, Reuterswärd C, Holm K, Jönsson M, Annersten K, Rosengren F, Jirström K, Kosieradzki J, Ek L, Borg Å, Planck M, Jönsson G, Staaf J.

Oncotarget. 2017 May 23;8(21):34796-34810. doi: 10.18632/oncotarget.16276.

36.

Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.

Boman K, Andersson G, Wennersten C, Nodin B, Ahlgren G, Jirström K.

Biomark Res. 2017 Mar 14;5:10. doi: 10.1186/s40364-017-0090-y. eCollection 2017.

37.

Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.

Grinberg M, Djureinovic D, Brunnström HR, Mattsson JS, Edlund K, Hengstler JG, La Fleur L, Ekman S, Koyi H, Branden E, Ståhle E, Jirström K, Tracy DK, Pontén F, Botling J, Rahnenführer J, Micke P.

Mod Pathol. 2017 Jul;30(7):964-977. doi: 10.1038/modpathol.2017.14. Epub 2017 Mar 10.

38.

Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition.

Caini S, Masala G, Saieva C, Kvaskoff M, Savoye I, Sacerdote C, Hemmingsson O, Hammer Bech B, Overvad K, Tjønneland A, Petersen KE, Mancini FR, Boutron-Ruault MC, Cervenka I, Kaaks R, Kühn T, Boeing H, Floegel A, Trichopoulou A, Valanou E, Kritikou M, Tagliabue G, Panico S, Tumino R, Bueno-de-Mesquita HB, Peeters PH, Veierød MB, Ghiasvand R, Lukic M, Quirós JR, Chirlaque MD, Ardanaz E, Salamanca Fernández E, Larrañaga N, Zamora-Ros R, Maria Nilsson L, Ljuslinder I, Jirström K, Sonestedt E, Key TJ, Wareham N, Khaw KT, Gunter M, Huybrechts I, Murphy N, Tsilidis KK, Weiderpass E, Palli D.

Int J Cancer. 2017 May 15;140(10):2246-2255. doi: 10.1002/ijc.30659. Epub 2017 Mar 9.

39.

Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma.

Fristedt R, Borg D, Hedner C, Berntsson J, Nodin B, Eberhard J, Micke P, Jirström K.

J Gastrointest Oncol. 2016 Dec;7(6):848-859. doi: 10.21037/jgo.2016.11.07.

40.

Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.

Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H.

Oncotarget. 2017 Feb 7;8(6):9093-9107. doi: 10.18632/oncotarget.14082.

41.

Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study.

Andersson G, Wennersten C, Borgquist S, Jirström K.

Biol Sex Differ. 2016 Dec 9;7:66. eCollection 2016.

42.

ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

Magnusson K, Gremel G, Rydén L, Pontén V, Uhlén M, Dimberg A, Jirström K, Pontén F.

BMC Cancer. 2016 Nov 18;16(1):904.

43.

Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer.

Ghanipour L, Jirström K, Sundström M, Glimelius B, Birgisson H.

Eur J Surg Oncol. 2017 Feb;43(2):311-321. doi: 10.1016/j.ejso.2016.10.013. Epub 2016 Oct 31.

PMID:
27836416
44.

High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy-Treated Patients-Results from a Population-Based Breast Cancer Cohort.

Elebro K, Borgquist S, Rosendahl AH, Markkula A, Simonsson M, Jirström K, Rose C, Ingvar C, Jernström H.

Clin Cancer Res. 2017 Feb 1;23(3):766-777. doi: 10.1158/1078-0432.CCR-16-1095. Epub 2016 Nov 3.

45.

Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer.

Englund E, Bartoschek M, Reitsma B, Jacobsson L, Escudero-Esparza A, Orimo A, Leandersson K, Hagerling C, Aspberg A, Storm P, Okroj M, Mulder H, Jirström K, Pietras K, Blom AM.

Oncogene. 2016 Oct 27;35(43):5585-5596. doi: 10.1038/onc.2016.98. Epub 2016 Apr 11.

PMID:
27065333
46.

Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer.

Escudero-Esparza A, Bartoschek M, Gialeli C, Okroj M, Owen S, Jirström K, Orimo A, Jiang WG, Pietras K, Blom AM.

Oncotarget. 2016 Nov 22;7(47):76920-76933. doi: 10.18632/oncotarget.12729.

47.

Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma.

Tran L, Mattsson JS, Nodin B, Jönsson P, Planck M, Jirström K, Botling J, Micke P, Brunnström H.

Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):648-659.

PMID:
26447895
48.

Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers.

Allaoui R, Bergenfelz C, Mohlin S, Hagerling C, Salari K, Werb Z, Anderson RL, Ethier SP, Jirström K, Påhlman S, Bexell D, Tahin B, Johansson ME, Larsson C, Leandersson K.

Nat Commun. 2016 Oct 11;7:13050. doi: 10.1038/ncomms13050.

49.

The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.

Simonsson M, Björner S, Markkula A, Nodin B, Jirström K, Rose C, Borgquist S, Ingvar C, Jernström H.

Int J Cancer. 2017 Jan 1;140(1):163-175. doi: 10.1002/ijc.30432. Epub 2016 Sep 28.

50.

Intra-tumour IgA1 is common in cancer and is correlated with poor prognosis in bladder cancer.

Welinder C, Jirström K, Lehn S, Nodin B, Marko-Varga G, Blixt O, Danielsson L, Jansson B.

Heliyon. 2016 Aug 16;2(8):e00143. doi: 10.1016/j.heliyon.2016.e00143. eCollection 2016 Aug.

Supplemental Content

Loading ...
Support Center